$0.47
-8.0%Purple Innovation, Inc. designs and manufactures mattresses, pillows, and cushions. The company also offers bases, foundations, sheets, mattress protectors, bed frames, seat cushions, weighted blankets, and duvets, as well as pet beds. It markets and sells its products through its e-commerce online channels retail brick-and-mortar wholesale partners, and third-party online retailers, as well as through Purple retail showrooms. The company was founded in 2010 and is headquartered in Lehi, Utah.
Strong gross margins indicate healthy pricing and efficient production or service delivery.
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
PRPL โข NASDAQ
| Purple Innovation, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||
468.7M | 487.9M | 510.5M | 573.2M | 726.2M | 648.5M | 428.4M | 285.8M | 196.9M | 65.5M | 5.8M | 4.3M | |
GROSS PROFIT | ||||||||||||
(280.2M) | (306.7M) | (338.7M) | (365.1M) | (431.3M) | (343.4M) | (239.4M) | (173.2M) | (111.8M) | (44M) | (4.5M) | (2.7M) | |
188.6M | 181.1M | 171.8M | 208.1M | 295M | 305.1M | 189M | 112.6M | 85M | 21.5M | 1.4M | 1.6M | |
OPERATING INCOME | ||||||||||||
(220.2M) | (273.3M) | (285.5M) | (250.8M) | (318.3M) | (233.9M) | (172.8M) | (129.5M) | (93.8M) | (2.7M) | (346K) | (847.7K) | |
(210.6M) | (240.4M) | (266.8M) | (242.1M) | (311.4M) | (227.9M) | (168.9M) | (127.4M) | (92.4M) | (2.7M) | (346K) | (844.4K) | |
(9.6M) | (13M) | (11.9M) | (8.8M) | (6.9M) | (6M) | (3.9M) | (2.1M) | (1.4M) | (792K) | (62K) | (3.4K) | |
-31.6M | -92.2M | -113.7M | -42.8M | -23.4M | 71.2M | 16.2M | -16.9M | -8.7M | -2.7M | -346K | 769.3K | |
PRE-TAX INCOME | ||||||||||||
(28.8M) | (17.5M) | (2M) | (3.5M) | (1.9M) | (4.7M) | (5.2M) | (3.7M) | (81K) | (0.0) | (0.0) | (0.0) | |
-28.8M | -17.5M | -2M | -3.5M | -1.9M | -4.7M | -5.2M | -3.7M | -81K | 0.0 | 0.0 | 0.0 | |
(0.0) | (20M) | (6.9M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-19.7M | -5.9M | -7.5M | 163.2M | 26M | -344.8M | -46.7M | -2.7M | -72K | 330K | 43K | -104.2K | |
-51.3M | -98M | -121.2M | 120.4M | 2.7M | -273.5M | -30.5M | -19.6M | -8.8M | -2.3M | -303K | 665.2K | |
NET INCOME | ||||||||||||
(207K) | (63K) | (8K) | (213.2M) | -1.2M | -43.7M | (400K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-51.4M | -97.9M | -120.8M | -92.5M | 4M | -236.9M | -22.6M | -4.3M | -8.8M | -2.3M | -303K | 665.2K |
PRPL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 11, 2026 | May 05, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | April 28, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 28, 2026 | April 24, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 22, 2026 | June 09, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 31, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 31, 2026 | March 24, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 05, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 04, 2025 | November 04, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 04, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 09, 2025 | September 08, 2025 | 2025 |
Continue your PRPL research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.